Literature DB >> 26204285

Understanding Cost-Effectiveness Analyses: An Explanation Using Three Different Analyses of Lung Cancer Screening.

Patti K Curl1, James G Kahn2, Karen G Ordovas1, Brett M Elicker1, David M Naeger1.   

Abstract

OBJECTIVE: Cost-effectiveness analyses (CEAs) contribute to informed decision making, at both the practitioner and societal levels; therefore, understanding CEAs is valuable for radiologists. In light of the recently published National Lung Cancer Screening Trial (NLST) CEA, we aim to explain the terminology, methods, and heterogeneity of CEAs.
CONCLUSION: We compared the NLST results to two example lung cancer screening CEAs (which do not rely on NLST data). Both examples assessed screening but reached substantially different conclusions.

Entities:  

Keywords:  cost-effectiveness analyses (CEAs); low-dose chest CT; lung cancer screening

Mesh:

Year:  2015        PMID: 26204285     DOI: 10.2214/AJR.14.14038

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  2 in total

Review 1.  2016 reflections on the favorable cost-benefit of lung cancer screening.

Authors:  Bruce Pyenson; Gabriela Dieguez
Journal:  Ann Transl Med       Date:  2016-04

2.  Magnetic Resonance Spectroscopy-based Metabolomic Biomarkers for Typing, Staging, and Survival Estimation of Early-Stage Human Lung Cancer.

Authors:  Yannick Berker; Lindsey A Vandergrift; Isabel Wagner; Li Su; Johannes Kurth; Andreas Schuler; Sarah S Dinges; Piet Habbel; Johannes Nowak; Eugene Mark; Martin J Aryee; David C Christiani; Leo L Cheng
Journal:  Sci Rep       Date:  2019-07-16       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.